Notch Therapeutics is pioneering the development of advanced T cell therapies, specifically through their innovative UNi-T Cell technology, which is derived from induced pluripotent stem cells (iPSCs). This approach addresses significant challenges associated with traditional adoptive cell therapies, which typically require the harvesting and genetic modification of T cells from individual patients. By utilizing a universal, off-the-shelf T cell product, Notch aims to provide a more consistent, cost-effective, and accessible solution for patients, thereby expanding the potential reach of CAR-T therapies beyond the current limitations.

The company's product pipeline includes promising candidates such as the CD19 + CD20 CAR UNi-T for treating B-cell non-Hodgkin lymphoma and autoimmune conditions, which is currently in the preclinical stage. Additionally, Notch is exploring other oncology products, including a DLL3 CAR product targeting small-cell lung cancer. Their collaboration with Allogene Therapeutics further enhances their capabilities in developing allogeneic iPSC-derived T cell therapies, positioning Notch Therapeutics as a key player in the evolving landscape of cell therapy.

Canada

Notch is an early-stage biotech company, working to maximize the benefit of cell therapies through a proprietary T cell-production platform which combines sophisticated product design with commercial-compatible processes to enhance patient outcomes. Notch’s iPSC-based technology platform allows for precision control of notch signaling, which removes several critical limiting factors in the development of cell therapies, delivering the ability to design and manufacture a uniform and unlimited supply of therapeutic T cells.

Notch Therapeutics

Company Details